Gujarat Themis Biosyn Financial Results
- Market cap
- ₹4,135 crore
- P/E
- 84.9
- P/B
- 14.37
- ROE
- 17.4%
- Dividend yield
- 0.18%
For the year ended Mar 2023, Gujarat Themis Biosyn reported revenue of ₹148 crore and net profit of ₹58 crore, against ₹170 crore and ₹59 crore a year earlier.
Gujarat Themis Biosyn annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | 148 | 170 | 151 | 166 | 174 |
| Expenses | 73 | 91 | 81 | 88 | 91 |
| Operating profit | 75 | 79 | 70 | 78 | 82 |
| Operating margin % | 51% | 47% | 46% | 47% | 47% |
| Other income | 5 | 4 | 2 | 1 | 2 |
| Interest | 0 | 0 | 0 | 3 | 5 |
| Depreciation | 3 | 4 | 5 | 13 | 15 |
| Profit before tax | 77 | 79 | 66 | 62 | 65 |
| Tax % | 25% | 25% | 26% | 25% | 25% |
| Net profit | 58 | 59 | 49 | 47 | 49 |
| EPS (₹) | 5.32 | 5.43 | 4.48 | 4.28 | 4.47 |
| Dividend payout % | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Gujarat Themis Biosyn financial results — frequently asked questions
What is Gujarat Themis Biosyn's annual revenue and net profit?
For the financial year ended Mar 2023, Gujarat Themis Biosyn's revenue was ₹148 crore and net profit ₹58 crore; net profit fell 1.69% from ₹59 crore in Mar 2024.
How fast has Gujarat Themis Biosyn grown over three years?
From Mar 2026 to Mar 2023, Gujarat Themis Biosyn's revenue grew at a compound annual rate of -3.8% and net profit at 7.3%. Past growth does not indicate future results.
What is the EPS of Gujarat Themis Biosyn?
Annual EPS for Mar 2023 was ₹5.32.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Gujarat Themis Biosyn With ATS
Track GUJTHEM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.